Zhejiang Hisun Pharmaceutical Co. Ltd. and Shanghai Aryl Pharmtech Co. Ltd. have disclosed bicyclic heteroaryl derivatives acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) allosteric inhibitors reported to be useful for the treatment of cancer, Noonan syndrome, LEOPARD syndrome, fibrosis, cardiovascular and immunological disorders.
Research led by Chalmers University of Technology and the Karolinska Institute in Sweden shows that glycosaminoglycans in the blood and urine can be used to detect 14 early-stage cancers.
Sinovent Inc. has divulged nitrogen-containing heterocyclic compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Glycomimetics Inc. has identified glycosides acting as galectin 3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, inflammation, thrombosis, cardiovascular disorders, transplant rejection, neurodegeneration, fibrosis and liver diseases, among other disorders.
NK cell-based cancer immunotherapy has emerged as an anticancer treatment approach and is currently being tested in clinical trials. KIR2DL5, a member of the human killer cell immunoglobulin-like receptor (KIR) family, has recently been identified as a binding partner for poliovirus receptor (PVR). However, the biology and therapeutic potential of the KIR2DL5/PVR pathway remain widely unexplored.
Previous research has shown that cytotoxic lymphocytes rely on gasdermin-mediated pyroptosis to kill tumor cells. Pyroptosis appears to be closely involved in anticancer immune response and has therefore emerged as a promising strategy for cancer treatment. In a recently published study, scientists at the University of Wisconsin-Madison aimed to leverage gasdermin-triggered pyroptosis for antitumor immunotherapy.
Researchers from Nalo Therapeutics Inc. presented the discovery and preclinical evaluation of a novel orally bioavailable and brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, NX-019, being developed as a potential therapeutic agent to treat EGFR-mutant solid tumors.
Nikang Therapeutics Inc. and Shanghai Blueray Biopharma Co. Ltd. have described exocyclic amino quinazoline derivatives acting as GTPase KRAS inhibitors, particularly KRAS (G12D mutant) inhibitors, reported to be useful for the treatment of cancer.
RSS
